Nanobiotix (NBTX) AI Stock Analysis

• Market Cap: $711.55M
• Dividend Yield: N/A
• Average Volume (3M): 45.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.92
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 47,943,150
• 10 Day Avg. Volume: 104,449
• 30 Day Avg. Volume: 45,987
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $11.00
• Price Target Upside: -25.42% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 56 Neutral
• Price Target: $6.50 ▼(-55.93% Downside)

Nanobiotix's stock score is primarily impacted by significant financial instability, marked by declining revenues and negative profitability. However, the stock's strong technical momentum provides a counterbalance, suggesting potential short-term interest despite the company's broader financial challenges. Valuation concerns persist due to the negative P/E ratio, reflecting non-profitability.

Positive Factors

Proprietary Technology

The proprietary nanotechnology platform provides a competitive edge in enhancing radiotherapy efficacy, potentially leading to strong market adoption.

Strategic Partnerships

Strategic partnerships with pharmaceutical companies can drive revenue growth through milestone payments and broaden market reach.

Industry Position

Focusing on cancer treatment enhancement positions Nanobiotix in a critical and growing sector, with potential for significant impact and demand.

Negative Factors

Financial Instability

Persistent net losses and negative equity indicate financial instability, raising concerns about the company's long-term viability and ability to sustain operations.

Negative Cash Flow

Negative cash flows constrain the company's ability to invest in growth opportunities and maintain liquidity, potentially impacting future operations.

High Leverage

High leverage and negative equity suggest potential solvency issues, limiting financial flexibility and increasing risk in economic downturns.

Nanobiotix Business Overview & Revenue Model

Company Description

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

How the Company Makes Money

Nanobiotix makes money primarily through the development and commercialization of its lead product, NBTXR3. The company generates revenue through collaborations, licensing agreements, and sales of its product to healthcare institutions and clinics. Key revenue streams include milestone payments from strategic partnerships, such as those with pharmaceutical companies that help to co-develop and distribute NBTXR3. Additionally, Nanobiotix may earn revenue through grants and funding from research institutions. The company's financial success is closely tied to the clinical success and market adoption of its products, as well as regulatory approvals in various jurisdictions.

Nanobiotix Financial Statement Overview

Summary

Nanobiotix exhibits significant financial challenges, including declining revenues, negative profitability, and a heavily leveraged balance sheet. The company faces persistent net losses, negative equity, and deteriorating cash flows, raising concerns about its long-term viability.

Income Statement

Nanobiotix shows significant revenue volatility, with a notable decline in total revenue from $36.2 million in 2023 to a negative $11.6 million in 2024. The gross profit margin is negative, and both EBIT and EBITDA margins are deeply negative, indicating operational losses. The company has been unable to achieve profitability, with a consistent net loss over the years.

Balance Sheet

The balance sheet reflects financial instability, with a negative stockholders' equity of $65.7 million in 2024. The significant increase in total liabilities, combined with persistent negative equity, suggests high leverage and potential solvency issues. The debt-to-equity ratio is not calculable due to negative equity, further highlighting financial distress.

Cash Flow

Nanobiotix's cash flow situation is concerning, with persistent negative operating and free cash flows. The free cash flow has deteriorated further from 2023 to 2024. Despite negative cash flows, the company has managed some financing activities, although these have decreased recently, potentially impacting liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-11.61M	36.21M	4.78M	10.00K	50.00K
Gross Profit	-11.61M	36.21M	3.79M	10.00K	50.00K
EBITDA	-58.32M	-23.69M	-45.15M	-45.60M	-31.49M
Net Income	-68.13M	-39.70M	-57.04M	-47.00M	-33.62M
Balance Sheet
Total Assets	67.42M	93.90M	59.77M	101.77M	134.03M
Cash, Cash Equivalents and Short-Term Investments	49.74M	75.28M	41.39M	83.92M	119.15M
Total Debt	50.90M	50.56M	53.17M	46.02M	48.98M
Total Liabilities	133.12M	95.74M	86.81M	74.98M	63.56M
Stockholders Equity	-65.70M	-1.84M	-27.05M	26.79M	70.47M
Cash Flow
Free Cash Flow	-20.40M	-12.81M	-37.20M	-30.11M	-27.64M
Operating Cash Flow	-19.55M	-12.48M	-37.10M	-29.87M	-27.54M
Investing Cash Flow	-955.00K	-349.00K	138.00K	-242.00K	-112.00K
Financing Cash Flow	-5.13M	46.77M	-5.65M	-5.18M	111.77M

Nanobiotix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NBTX, the sentiment is Positive. The current price of 14.75 is above the 20-day moving average (MA) of 10.55, above the 50-day MA of 8.64, and above the 200-day MA of 4.94, indicating a bullish trend. The MACD of 1.69 indicates Negative momentum. The RSI at 69.86 is Neutral, neither overbought nor oversold. The STOCH value of 84.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NBTX.

Nanobiotix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NBTX	56 Neutral	$711.55M	―	2152.93%	―	―	―
SGMO	51 Neutral	170.44M	-2.23	-430.13%	―	565.52%	79.44%
IPHA	51 Neutral	174.43M	-3.05	-560.01%	―	-75.77%	-31.24%
DSGN	47 Neutral	366.75M	-5.46	―	―	―	-24.60%
MOLN	44 Neutral	143.84M	-1.73	-38.16%	―	-91.15%	-5.82%
ANNX	38 Underperform	309.88M	-2.17	―	―	―	-5.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Nanobiotix Corporate Events

Nanobiotix Reveals Promising Phase 1 Results for Melanoma Treatment

On September 17, 2025, Nanobiotix announced new results from a Phase 1 study evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors for patients with primary cutaneous melanoma resistant to anti-PD-1. The study showed a favorable safety profile and early efficacy signals, with a 47.4% objective response rate and a 78.9% disease control rate. The findings suggest potential for further investigation in randomized clinical trials, potentially offering new treatment options for patients with advanced melanoma.

Nanobiotix Updates Voting Rights and Share Capital Information

On September 12, 2025, Nanobiotix announced its updated voting rights and share capital information, reporting 48,236,771 shares outstanding as of August 31, 2025. The announcement, in compliance with French financial regulations, provides transparency to stakeholders and reinforces the company’s commitment to regulatory standards, potentially impacting its market positioning and investor relations.

Nanobiotix to Present at H.C. Wainwright Investment Conference

On September 2, 2025, Nanobiotix announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 9, 2025, in New York. The company’s CEO, Laurent Levy, and CFO, Bart van Rhijn, will present at the event, which will be webcast live. This participation underscores Nanobiotix’s ongoing efforts to engage with investors and stakeholders, potentially impacting its market visibility and investor relations.

Nanobiotix Announces Voting Rights and Share Capital Update

On August 27, 2025, Nanobiotix announced its voting rights and share capital details, revealing 48,236,671 shares outstanding as of July 31, 2025. The announcement provides transparency to stakeholders and aligns with regulatory requirements, potentially impacting investor confidence and market positioning.

Nanobiotix Advances JNJ-1900 with Regulatory and Patent Milestones

On July 7, 2025, Nanobiotix announced significant regulatory and intellectual property advancements for its potential first-in-class radioenhancer, JNJ-1900 (NBTXR3). The product has been reclassified from a medical device to a medicinal product in major European countries, aligning its status with the US and other markets, which supports a unified global regulatory strategy. Additionally, a new composition of matter patent has been filed to strengthen its intellectual property. These developments are expected to enhance the global positioning of JNJ-1900, which is undergoing a comprehensive clinical development program, including a pivotal Phase 3 trial in head and neck cancer.

Nanobiotix Allocates Free Shares to Executives

Nanobiotix, a company involved in the biotechnology industry, has disclosed transactions involving the allocation of free shares to key executives. On June 27, 2025, several transactions were made outside trading platforms, involving the allocation of free shares to individuals in managerial roles, including the CEO and other executives. This move, disclosed on July 2, 2025, is part of the company’s strategy to align management incentives with company performance, potentially impacting stakeholder perceptions and market positioning.